Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03463473 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of MSB2311 in Advanced Solid Tumors
A Phase 1 study, sponsored by Suzhou Transcenta Therapeutics Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT03463473 is a Phase 1 study that has completed, run by Suzhou Transcenta Therapeutics Co.. The registered enrollment target is 42 participants.
The verdict
NCT03463473, a Phase 1 study, has completed, sponsored by Suzhou Transcenta Therapeutics Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This is a phase I study to determine the safety and toxicity, PK/PD, immunogenicity, biomarkers, anti-tumor activity and establish a preliminary recommended Phase 2 dose (RP2D) in subjects with advanced solid tumors.
Interventions
- DRUG 3 mg/kg Q3W MSB2311 Injection
- DRUG 10 mg/kg Q3W MSB2311 Injection
- DRUG 20 mg/kg Q3W MSB2311 Injection
- DRUG 10 mg/kg Q2W MSB2311 Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2018-04-12 |
| Est. Completion | 2020-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03463473
The ClinicalTrials.gov registry entry for NCT03463473 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Suzhou Transcenta Therapeutics Co., which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which 3 mg/kg Q3W MSB2311 Injection is the first listed.
NCT03463473 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03463473 about?
NCT03463473 is a clinical study titled "A Phase I Study of MSB2311 in Advanced Solid Tumors". This is a phase I study to determine the safety and toxicity, PK/PD, immunogenicity, biomarkers, anti-tumor activity and establish a preliminary recommended Phase 2 dose (RP2D) in subjects with advanced solid tumors.
What is the current status of trial NCT03463473?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2018-04-12. Estimated completion is 2020-06-01.
What interventions are being tested in trial NCT03463473?
The interventions under investigation include: 3 mg/kg Q3W MSB2311 Injection (DRUG), 10 mg/kg Q3W MSB2311 Injection (DRUG), 20 mg/kg Q3W MSB2311 Injection (DRUG), 10 mg/kg Q2W MSB2311 Injection (DRUG).
Who is sponsoring clinical trial NCT03463473?
This trial is sponsored by Suzhou Transcenta Therapeutics Co., which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.